
    
      This is a phase II single institution trial in patients with newly diagnosed multiple
      myeloma. RevlimidÂ® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg
      p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D..
    
  